Biofrontera Inc. Operating Cash Flow
Biofrontera Inc. (BFRI) reported Operating Cash Flow of -$1.73 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- Biofrontera Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$1.66M.
- Biofrontera Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$70.00K.
- Biofrontera Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$2.38M.
- Biofrontera Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$3.82M.
- Biofrontera Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$13.36M.
- Biofrontera Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$10.27M.
- Biofrontera Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$24.89M.
- Biofrontera Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$16.20M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$1.73M 10-Q · filed 2026-08-13 | -$4.10M derived: sum of 3 quarters · filed 2026-08-13 | -$7.93M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$70.00K 10-Q · filed 2026-05-14 | -$2.45M derived: sum of 2 quarters · filed 2026-05-14 | -$6.27M derived: sum of 3 quarters · filed 2026-05-14 | -$9.31M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$2.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$6.20M derived: sum of 2 quarters · filed 2026-03-19 | -$9.24M derived: sum of 3 quarters · filed 2026-08-13 | -$13.36M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$3.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$6.87M derived: sum of 2 quarters · filed 2026-08-13 | -$10.98M 10-Q · filed 2025-11-12 | -$12.00M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$3.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$7.16M 10-Q · filed 2026-08-13 | -$8.18M derived: sum of 3 quarters · filed 2026-08-13 | -$9.39M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$4.12M 10-Q · filed 2026-05-14 | -$5.13M derived: sum of 2 quarters · filed 2026-05-14 | -$6.34M derived: sum of 3 quarters · filed 2026-05-14 | -$11.06M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$1.02M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$2.23M derived: sum of 2 quarters · filed 2026-03-19 | -$6.95M derived: sum of 3 quarters · filed 2026-03-19 | -$10.27M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$1.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$5.93M derived: sum of 2 quarters · filed 2025-11-12 | -$9.25M 10-Q · filed 2025-11-12 | -$18.12M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$4.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$8.04M 10-Q · filed 2025-08-13 | -$16.91M derived: sum of 3 quarters · filed 2025-08-13 | -$18.91M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$3.33M 10-Q · filed 2025-05-15 | -$12.19M derived: sum of 2 quarters · filed 2025-05-15 | -$14.20M derived: sum of 3 quarters · filed 2025-05-15 | -$24.53M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$8.87M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$10.87M derived: sum of 2 quarters · filed 2025-03-20 | -$21.21M derived: sum of 3 quarters · filed 2025-03-20 | -$24.89M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$12.34M derived: sum of 2 quarters · filed 2024-11-14 | -$16.03M 10-Q · filed 2024-11-14 | -$24.30M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$10.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$14.03M 10-Q · filed 2024-08-14 | -$22.30M derived: sum of 3 quarters · filed 2024-08-14 | -$28.24M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$3.69M 10-Q · filed 2024-05-15 | -$11.96M derived: sum of 2 quarters · filed 2024-05-15 | -$17.90M derived: sum of 3 quarters · filed 2024-05-15 | -$17.78M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$8.27M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | -$14.21M derived: sum of 2 quarters · filed 2024-03-15 | -$14.09M derived: sum of 3 quarters · filed 2024-03-15 | -$16.20M 10-K · filed 2024-03-15 |
| 2022-09-30 | -$5.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$5.82M derived: sum of 2 quarters · filed 2023-11-09 | -$7.93M 10-Q · filed 2023-11-09 | -$28.92M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $125.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$1.99M 10-Q · filed 2023-08-11 | -$22.98M derived: sum of 3 quarters · filed 2023-10-03 | -$24.19M derived: sum of 4 quarters · filed 2023-10-03 |
| 2022-03-31 | -$2.11M 10-Q · filed 2023-05-12 | -$23.10M derived: sum of 2 quarters · filed 2023-10-03 | -$24.32M derived: sum of 3 quarters · filed 2023-10-03 | -$25.38M derived: sum of 4 quarters · filed 2023-10-03 |
| 2021-12-31 | -$20.99M derived: 8-K 12 month − 10-Q 9 month · filed 2023-10-03 | -$22.21M derived: sum of 2 quarters · filed 2023-10-03 | -$23.27M derived: sum of 3 quarters · filed 2023-10-03 | -$26.71M 8-K · filed 2023-10-03 |
| 2021-09-30 | -$1.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$2.28M derived: sum of 2 quarters · filed 2022-11-14 | -$5.72M 10-Q · filed 2022-11-14 | -$6.39M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | -$1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$4.51M 10-Q · filed 2022-08-12 | -$5.17M derived: sum of 3 quarters · filed 2022-08-12 | |
| 2021-03-31 | -$3.44M 10-Q · filed 2022-05-13 | -$4.11M derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2020-12-31 | -$663.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-04-11 | -$12.37M 10-K · filed 2022-04-11 | ||
| 2020-09-30 | -$11.71M 10-Q · filed 2021-11-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B |